{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:21Z","timestamp":1793093601690,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019175","name":"Scleroderma Society of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018948","name":"Saudi Arabian Cultural Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.berh.2026.102138","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:48:27Z","timestamp":1775533707000},"page":"102138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Renal involvement in systemic sclerosis"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7851-1504","authenticated-orcid":false,"given":"Ibraheem M.","family":"Almani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102138_bib1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3390\/jpm12071123","article-title":"Kidney involvement in systemic sclerosis","volume":"12","author":"Reggiani","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.berh.2026.102138_bib2","first-page":"S54","article-title":"Systemic sclerosis and interstitial lung disease: from pathogenesis, to screening, diagnosis, and classification","volume":"31","author":"Codes","year":"2024","journal-title":"Rev Colomb Reumatol Engl Ed"},{"key":"10.1016\/j.berh.2026.102138_bib3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3899\/jrheum.151353","article-title":"The frequency of scleroderma renal crisis over time: a metaanalysis","volume":"43","author":"Turk","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib4","series-title":"StatPearls","article-title":"Scleroderma and renal crisis","author":"Basyal","year":"2025"},{"key":"10.1016\/j.berh.2026.102138_bib5","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/ndt\/gfs317","article-title":"Prognosis of scleroderma renal crisis: a long-term observational study","volume":"27","author":"Cozzi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2026.102138_bib6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.berh.2026.102138_bib7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib8","series-title":"StatPearls","article-title":"Systemic sclerosis (Scleroderma)","author":"Adigun","year":"2025"},{"key":"10.1016\/j.berh.2026.102138_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102138_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","article-title":"Renal disease and systemic sclerosis: an update on scleroderma renal crisis","volume":"64","author":"Cole","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102138_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ijlh.13954","article-title":"Diagnosis and treatment of thrombotic microangiopathy","volume":"44","author":"Thompson","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.berh.2026.102138_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12882-019-1467-y","article-title":"Systemic sclerosis medications and risk of scleroderma renal crisis","volume":"20","author":"Gordon","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.berh.2026.102138_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/jcpt.13621","article-title":"Angiotensin\u2010converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: a systematic review and meta\u2010analysis","volume":"47","author":"Xiong","year":"2022","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.berh.2026.102138_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.berh.2026.102138_bib16","series-title":"The history of ACE inhibitors in scleroderma renal crisis","author":"Hickman","year":"2021"},{"key":"10.1016\/j.berh.2026.102138_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12243-9","article-title":"Analysis of related deaths in patients with systemic sclerosis combined with renal failure in the United States from 1999 to 2020","volume":"15","author":"Huo","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102138_bib18","article-title":"Epidemiology of systemic sclerosis in Quebec, Canada: a population-based study","volume":"35","author":"Muntyanu","year":"2024","journal-title":"Lancet Reg Health, Am"},{"key":"10.1016\/j.berh.2026.102138_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2397198320920422","article-title":"Mortality and morbidity in scleroderma renal crisis: a systematic literature review","volume":"6","author":"Kim","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102138_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13075-024-03408-4","article-title":"Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents","volume":"26","author":"Del Papa","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102138_bib21","series-title":"Oxford textbook of rheumatology","first-page":"971","article-title":"Systemic sclerosis","author":"Denton","year":"2013"},{"key":"10.1016\/j.berh.2026.102138_bib22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/biomedicines13071771","article-title":"Systemic sclerosis: a key model of endothelial dysfunction","volume":"13","author":"Zaccone","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.berh.2026.102138_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.788250","article-title":"Management of endothelial dysfunction in systemic sclerosis: current and developing strategies","volume":"8","author":"Zanin-Silva","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.berh.2026.102138_bib24","first-page":"1","article-title":"Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy","volume":"2010","author":"Shanmugam","year":"2010","journal-title":"Internet J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.autrev.2009.02.002","article-title":"Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression","volume":"8","author":"Cavazzana","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102138_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5114\/ada.2020.102107","article-title":"Clinical consequences of the presence of anti-RNA pol III antibodies in systemic sclerosis","volume":"37","author":"Wielosz","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.berh.2026.102138_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/ojra.2013.32017","article-title":"Associations with organ involvement and autoantibodies in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG)","volume":"3","author":"Tangri","year":"2013","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"10.1016\/j.berh.2026.102138_bib28","article-title":"Clinical phenotype of systemic sclerosis patients with Anti-RNA polymerase III antibodies: a new French cohort","author":"Sobanski","year":"2014","journal-title":"Systematic Rev Meta-Anal"},{"key":"10.1016\/j.berh.2026.102138_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102138_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2397198318758607","article-title":"Kidney involvement in systemic sclerosis: from pathogenesis to treatment","volume":"3","author":"Bruni","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102138_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2011.569753","article-title":"Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort","volume":"40","author":"Emilie","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib32","first-page":"keaf392","article-title":"Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis","author":"Elhannani","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102138_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.090677","article-title":"Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study","volume":"37","author":"Meyer","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.rdc.2020.03.002","article-title":"Cancer and scleroderma","volume":"46","author":"Weeding","year":"2020","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.berh.2026.102138_bib35","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102138_bib36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/biomedicines13040993","article-title":"Malignancy in systemic sclerosis: a multicenter retrospective study","volume":"13","author":"Nemes-T\u00f6m\u00f6ri","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.berh.2026.102138_bib37","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.5152\/eurjrheum.2019.19158","article-title":"Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis","volume":"7","author":"Ota","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s44320-025-00116-2","article-title":"Dynamic multi-omics and mechanistic modeling approach uncovers novel mechanisms of kidney fibrosis progression","volume":"21","author":"Tuechler","year":"2025","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.berh.2026.102138_bib39","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1172\/JCI43025","article-title":"Epithelial notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans","volume":"120","author":"Bielesz","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102138_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005233","article-title":"Jagged1\/Notch2 controls kidney fibrosis via Tfam-mediated metabolic reprogramming","volume":"16","author":"Huang","year":"2018","journal-title":"PLoS Biol"},{"key":"10.1016\/j.berh.2026.102138_bib41","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/ijms23073904","article-title":"PDGF\/PDGFR: a possible molecular target in Scleroderma fibrosis","volume":"23","author":"Paolini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2026.102138_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/678180","article-title":"The importance of C4d in biopsies of kidney transplant recipients","volume":"2013","author":"Corr\u00eaa","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.berh.2026.102138_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2026.102138_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.berh.2026.102138_bib45","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1309\/LM72AM5XFHZYOQCB","article-title":"Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade","volume":"46","author":"Keeler","year":"2015","journal-title":"Lab Med"},{"key":"10.1016\/j.berh.2026.102138_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103330","article-title":"Renal involvement in systemic sclerosis","volume":"22","author":"Scheen","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102138_bib47","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/jdv.20101","article-title":"Update of the guidelines for sclerosing skin diseases","volume":"38","author":"De Jong","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102138_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ekir.2016.07.005","article-title":"Scleroderma renal crisis in a normotensive patient","volume":"1","author":"Asamoah-Odei","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.berh.2026.102138_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202566","article-title":"Mistaken identity: normotensive scleroderma renal crisis","volume":"2014","author":"Aburizik","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2026.102138_bib50","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00296-008-0807-1","article-title":"A \u201csilent\u201d course of normotensive scleroderma renal crisis: case report and review of the literature","volume":"29","author":"Akoglu","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2026.102138_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European scleroderma trials and research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102138_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206675","article-title":"Steroid-induced scleroderma renal crisis in an at-risk patient","volume":"2014","author":"Toescu","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2026.102138_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4274\/qrheumatol.galenos.2023.87587","article-title":"Scleroderma renal crisis","volume":"1","author":"Akdo\u011fan","year":"2023","journal-title":"Rheumatol Q"},{"key":"10.1016\/j.berh.2026.102138_bib54","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.30111","article-title":"HLA\u2013DRB1*0407 and *1304 are risk factors for scleroderma renal crisis","volume":"63","author":"Nguyen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102138_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma renal crisis: a pathology perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"Internet J Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0039-1688422","article-title":"Complications of percutaneous renal biopsy","volume":"36","author":"Bakdash","year":"2019","journal-title":"Semin Interv Radiol"},{"key":"10.1016\/j.berh.2026.102138_bib57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s40674-014-0004-1","article-title":"Management of renal involvement in scleroderma","volume":"1","author":"Stern","year":"2015","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib58","first-page":"279","article-title":"Scleroderma renal crisis: importance of knowing and differentiating in emergency unit","volume":"14","author":"Alenzi","year":"2019","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102138_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/om.2011.110061","article-title":"Hypertension in pregnancy: a review of therapeutic options","volume":"5","author":"Kernaghan","year":"2012","journal-title":"Obstet Med"},{"key":"10.1016\/j.berh.2026.102138_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2463583","article-title":"Bibliometric insights into systemic sclerosis with renal involvement: trends, contributions, and future directions","volume":"47","author":"Huang","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.berh.2026.102138_bib61","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1038\/s41467-025-60034-7","article-title":"Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis","volume":"16","author":"Shimagami","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102138_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1176856","article-title":"Multi-omic single cell sequencing: overview and opportunities for kidney disease therapeutic development","volume":"10","author":"Pregizer","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.berh.2026.102138_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102138_bib64","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.2147\/JIR.S379815","article-title":"Biomarkers in the pathogenesis, diagnosis, and treatment of systemic sclerosis","volume":"16","author":"Muruganandam","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.berh.2026.102138_bib65","series-title":"StatPearls","article-title":"Physiology, endothelin","author":"Titus","year":"2025"},{"key":"10.1016\/j.berh.2026.102138_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152256","article-title":"Studying the role of C5-Inhibition therapy in scleroderma renal crisis-induced thrombotic microangiopathy \u2013 a review of literature","volume":"63","author":"Farrukh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102138_bib67","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/ard.2010.144360","article-title":"Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres","volume":"70","author":"Fransen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102138_bib68","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European scleroderma trials and research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:03:55Z","timestamp":1785891835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1521694226000239"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102138","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal involvement in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102138"}}